,19 Two pharmacological ezrin inhibitors have been better characterized in cancer models, NSC305787 and NSC668394, with NSC305787 being considered more potent and with a more favorable pharmacokinetic profile,6,7 which led us to choose this compound for the studies in vitro in models of cervical and gastric cancer. This evidence concerns the gene EZR and cancer.